KRAS and angiosarcoma: 53% of angiosarcomas displayed MAPK pathway activation, and harboured genetic activating mutations in KRAS, HRAS, NRAS, BRAF, MAPK1 or inactivating mutations in NF1 and PTPRB1 [19, 20].